

FILE 'REGISTRY' ENTERED AT 12:35:55 ON 06 OCT 2008

EXP LANSOPRAZOLE/CN

L1 1 S E3

EXP ETHYLENEDIAMINETETRAACET/CN

L2 1 S E5

EXP N-METHYLGLUC/CN

L3 1 S E4

FILE 'HCAPLUS' ENTERED AT 12:37:02 ON 06 OCT 2008

L4 0 S L1 AND L2

FILE 'REGISTRY' ENTERED AT 12:37:23 ON 06 OCT 2008

EXP ETHYLENEDIAMINETETRAACET/CN

L5 1 S E10

EXP ETHYLENEDIAMINETETRAACETIC ACID SOD/CN

EXP ETHYLENEDIAMINETETRAACETIC ACID SOD/CN

L6 1 S E4

FILE 'HCAPLUS' ENTERED AT 12:38:45 ON 06 OCT 2008

L7 0 S L1 AND L6

L8 15 S L1 AND L5

L9 7 S L8 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file registry
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 12:35:55 ON 06 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 OCT 2008 HIGHEST RN 1057399-47-9
DICTIONARY FILE UPDATES: 5 OCT 2008 HIGHEST RN 1057399-47-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> exp lansoprazole/cn

E1	1	LANSOPEP/CN
E2	1	LANSOPHED/CN
E3	1 -->	LANSOPRAZOLE/CN
E4	1	LANSOPRAZOLE CALCIUM/CN
E5	1	LANSOPRAZOLE SODIUM/CN
E6	1	LANSOPRAZOLE SULFIDE/CN
E7	1	LANSOPRAZOLE SULFONE/CN
E8	1	LANSOPRAZOLE-AMOXICILLIN MIXT./CN
E9	1	LANSOPRAZOLE-CLARITHROMYCIN MIXT./CN
E10	1	LANSOPRAZOLE-LEVOFLOXACIN MIXT./CN
E11	1	LANSOPRAZOLE-SITAFLOXACIN MIXT./CN
E12	1	LANSOPRID/CN

=> s e3

L1	1	LANSOPRAZOLE/CN
----	---	-----------------

=> exp ethylenediaminetetraacet/cn

E1	1	ETHYLENEDIAMINETETRA(METHYLPHOSPHONIC ACID) MONOHYDRATE/CN
E2	1	ETHYLENEDIAMINETETRA-3-PROPIONIC ACID/CN
E3	0 -->	ETHYLENEDIAMINETETRAACET/CN
E4	1	ETHYLENEDIAMINETETRAACETAMIDE/CN
E5	1	ETHYLENEDIAMINETETRAACETATE/CN
E6	1	ETHYLENEDIAMINETETRAACETATOCOBALTATE(III)/CN
E7	1	ETHYLENEDIAMINETETRAACETATOINDATE(1-)/CN
E8	1	ETHYLENEDIAMINETETRAACETATOVANADATE(1-)/CN
E9	1	ETHYLENEDIAMINETETRAACETDIDODECYLIMIDE/CN
E10	1	ETHYLENEDIAMINETETRAACETIC ACID/CN
E11	1	ETHYLENEDIAMINETETRAACETIC ACID ANHYDRIDE-ETHYLENEDIAMINE CO POLYMER/CN
E12	1	ETHYLENEDIAMINETETRAACETIC ACID BARIUM SALT/CN

```
=> s e5
L2          1 ETHYLENEDIAMINETETRAACETATE/CN

=> exp N-methylgluc/cn
E1          1      N-METHYLGLAUCINE IODIDE/CN
E2          1      N-METHYLGLAUDINIUM IODIDE/CN
E3          0 --> N-METHYLGLUC/CN
E4          1      N-METHYLGLUCAMINE/CN
E5          1      N-METHYLGLUCAMINE 5,5'-(DODECANEDIOYLDIIMINO)-BIS(2,4,6-TRII
            ODO-N-METHYLISOPHTHALAMATE)/CN
E6          1      N-METHYLGLUCAMINE ACETYLSALICYLATE/CN
E7          1      N-METHYLGLUCAMINE ANTIMONATE/CN
E8          1      N-METHYLGLUCAMINE CYCLOHEXYLSULFAMATE/CN
E9          1      N-METHYLGLUCAMINE DIATRIZOATE/CN
E10         1      N-METHYLGLUCAMINE HYDROCHLORIDE/CN
E11         1      N-METHYLGLUCAMINE IODOMETHANESULFONATE/CN
E12         1      N-METHYLGLUCAMINE IOTHALAMATE/CN
```

```
=> s e4
L3          1 N-METHYLGLUCAMINE/CN
```

```
=> file hcaplus
COST IN U.S. DOLLARS          SINCE FILE          TOTAL
                               ENTRY          SESSION
FULL ESTIMATED COST          16.37          16.58
```

FILE 'HCAPLUS' ENTERED AT 12:37:02 ON 06 OCT 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Oct 2008 VOL 149 ISS 15
 FILE LAST UPDATED: 5 Oct 2008 (20081005/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l1 and l2
          1904 L1
          100 L2
L4          0 L1 AND L2
```

```
=> file registry
COST IN U.S. DOLLARS          SINCE FILE          TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	2.69	19.27

FILE 'REGISTRY' ENTERED AT 12:37:23 ON 06 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 OCT 2008 HIGHEST RN 1057399-47-9
DICTIONARY FILE UPDATES: 5 OCT 2008 HIGHEST RN 1057399-47-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> exp ethylenediaminetetraacet/cn

E1	1	ETHYLENEDIAMINETETRA(METHYLPHOSPHONIC ACID) MONOHYDRATE/CN
E2	1	ETHYLENEDIAMINETETRA-3-PROPIONIC ACID/CN
E3	0 -->	ETHYLENEDIAMINETETRAACET/CN
E4	1	ETHYLENEDIAMINETETRAACETAMIDE/CN
E5	1	ETHYLENEDIAMINETETRAACETATE/CN
E6	1	ETHYLENEDIAMINETETRAACETATOCOBALTATE(III)/CN
E7	1	ETHYLENEDIAMINETETRAACETATOINDATE(1-)/CN
E8	1	ETHYLENEDIAMINETETRAACETATOVANADATE(1-)/CN
E9	1	ETHYLENEDIAMINETETRAACETDIDODECYLIMIDE/CN
E10	1	ETHYLENEDIAMINETETRAACETIC ACID/CN
E11	1	ETHYLENEDIAMINETETRAACETIC ACID ANHYDRIDE-ETHYLENEDIAMINE CO POLYMER/CN
E12	1	ETHYLENEDIAMINETETRAACETIC ACID BARIUM SALT/CN

=> s e10

L5	1	"ETHYLENEDIAMINETETRAACETIC ACID"/CN
----	---	--------------------------------------

=> exp ethylenediaminetetraacetic acid sod/cn

E1	1	ETHYDINE/CN
E2	1	ETHYDRONATE/CN
E3	0 -->	ETHYENEDIAMINETETRAACETIC ACID SOD/CN
E4	1	ETHYL/CN
E5	1	ETHYL (((((1S)-1-(1H-BENZIMIDAZOL-2-YL)-2-(4-(1,1-DIOXIDO-3- OXOISOTHIAZOLIDIN-5-YL)PHENYL)ETHYL)AMINO)CARBONYL)AMINO)ACE TATE TRIFLUOROACETATE/CN
E6	1	ETHYL (((((2-((4-CHLOROPHENYL)OXY)ETHYL)AMINO)CARBONYL)OXY)AC ETATE/CN
E7	1	ETHYL (((((2-(3-PHENYLOXYPHENYL)ETHYL)AMINO)CARBONYL)OXY)ACET ATE/CN
E8	1	ETHYL (((((5-(((TERT-BUTOXYCARBONYL)AMINO)METHYL)-6-ISOBUTYL- 2-METHYL-4-(4-METHYLPHENYL)PYRIDIN-3-YL)AMINO)CARBONYL)OXY)A CETATE/CN

```

E9          1      ETHYL (((5-(AMINOMETHYL)-6-ISOBUTYL-2-METHYL-4-(4-METHYLPHE
NYL)PYRIDIN-3-YL)AMINO)CARBONYL)OXY)ACETATE DIHYDROCHLORIDE/
CN
E10         1      ETHYL (((TERT-BUTOXYCARBONYL)AMINO)SULFONYL)(4-((2S)-2-((TE
RT-BUTOXYCARBONYL)AMINO)-2-(5-(TRIFLUOROMETHYL)-1H-BENZIMIDA
ZOL-2-YL)ETHYL)-2-CHLOROPHENYL)AMINO)ACETATE TRIFLUOROACETAT
E/CN
E11         1      ETHYL (((TERT-BUTOXYCARBONYL)AMINO)SULFONYL)(4-((2S)-2-((TE
RT-BUTOXYCARBONYL)AMINO)-2-(5-(TRIFLUOROMETHYL)-1H-BENZIMIDA
ZOL-2-YL)ETHYL)PHENYL)AMINO)ACETATE TRIFLUOROACETATE/CN
E12         1      ETHYL (((1-((CYCLOHEXYLAMINO)CARBONYL)PIPERIDIN-4-YL)METHYL)
(4-((DODECYLAMINO)CARBONYL)BENZYL)AMINO)(OXO)ACETATE/CN

```

```
=> exp ethylenediaminetetraacetic acid sod/cn
```

```

E1          1      ETHYLENEDIAMINETETRAACETIC ACID N,N'-DIOXIDE/CN
E2          1      ETHYLENEDIAMINETETRAACETIC ACID POTASSIUM SALT/CN
E3          0  --> ETHYLENEDIAMINETETRAACETIC ACID SOD/CN
E4          1      ETHYLENEDIAMINETETRAACETIC ACID SODIUM SALT/CN
E5          1      ETHYLENEDIAMINETETRAACETIC ACID SYM-BIS(N-(B-MERCAPTOET
HYL)AMIDE)/CN
E6          1      ETHYLENEDIAMINETETRAACETIC ACID SYM-BIS(N-(B-MERCAPTOET
HYL)AMIDE), POLYMER/CN
E7          1      ETHYLENEDIAMINETETRAACETIC ACID SYM-BIS(N-METHYLAMIDE)/CN
E8          1      ETHYLENEDIAMINETETRAACETIC ACID TETRAAMMONIUM SALT/CN
E9          1      ETHYLENEDIAMINETETRAACETIC ACID TETRAHYDRAZIDE/CN
E10         1      ETHYLENEDIAMINETETRAACETIC ACID TETRAPOTASSIUM SALT/CN
E11         1      ETHYLENEDIAMINETETRAACETIC ACID TETRASODIUM SALT/CN
E12         1      ETHYLENEDIAMINETETRAACETIC ACID TRIAMMONIUM SALT/CN

```

```
=> s e4
```

```
L6          1      "ETHYLENEDIAMINETETRAACETIC ACID SODIUM SALT"/CN
```

```
=> file hcaplus
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.22	30.49

```
FILE 'HCAPLUS' ENTERED AT 12:38:45 ON 06 OCT 2008
```

```
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

```
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

```
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 6 Oct 2008 VOL 149 ISS 15
```

```
FILE LAST UPDATED: 5 Oct 2008 (20081005/ED)
```

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 11 and 16
1904 L1
1335 L6
L7 0 L1 AND L6

=> s 11 and 15
1904 L1
34216 L5
L8 15 L1 AND L5

=> s 18 and (PY<2004 or AY<2004 or PRY<2004)
24009717 PY<2004
4787037 AY<2004
4258419 PRY<2004
L9 7 L8 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> d 19 1-7 ti abs bib

L9 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Injectable composition comprising lansoprazole and a chelating agent
AB An injectable composition comprising a combination of lansoprazole, its optically active isomer, or a salt thereof, and a chelating agent, which is used at pH 9 to 12. The injectable composition has excellent stability and solubility, and has such a high-quality that particulate insolubles are not formed when the composition is kept and supplied in a glass container and even in a plastic container and also when the composition is kept in these containers for a long time. Thus, a composition contained lansoprazole 30, N-methylglucamine 10, mannitol 60, and NaOH 3.45 mg and water for injection 5 mL.

AN 2005:567110 HCAPLUS <<LOGINID::20081006>>

DN 143:65527

TI Injectable composition comprising lansoprazole and a chelating agent

IN Doen, Takayuki; Inoue, Tomoko

PA Takeda Pharmaceutical Company Limited, Japan

SO PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2005058277	A1	20050630	WO 2004-JP18956	20041213 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2548074	A1	20050630	CA 2004-2548074	20041213 <--
	JP 2005200409	A	20050728	JP 2004-359283	20041213 <--
	EP 1694296	A1	20060830	EP 2004-807313	20041213 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				

US 20070191286 A1 20070816 US 2006-583321 20060616 <--
 PRAI JP 2003-419288 A 20031217 <--
 WO 2004-JP18956 W 20041213
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Film comprising therapeutic agents
 AB The present invention is related to the composition and methods of manufacture
 of

orally-dissolvable, edible films as a vehicle for the non-invasive
 administration of nitroglycerin, as well as other therapeutic agents
 either with or without nitroglycerin, through the mucosal tissues of the
 oral cavity. The films include a water-soluble film-forming polymer, such as
 pullulan. Methods for producing the films are also disclosed.

AN 2005:55116 HCAPLUS <<LOGINID::20081006>>

DN 142:141267

TI Film comprising therapeutic agents

IN Maibach, Todd

PA USA

SO PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005004989	A2	20050120	WO 2004-US21038	20040630 <--
	WO 2005004989	A3	20050616		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2530843	A1	20050120	CA 2004-2530843	20040630 <--
	EP 1648362	A2	20060426	EP 2004-777314	20040630 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	CN 1829490	A	20060906	CN 2004-80022053	20040630 <--
	US 20070059346	A1	20070315	US 2006-562633	20060609 <--
PRAI	US 2003-484009P	P	20030701	<--	
	US 2003-497426P	P	20030821	<--	
	WO 2004-US21038	W	20040630		

L9 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Fast dissolving orally consumable films containing a sweetener
 AB A consumable film adapted to adhere to and dissolve in the oral cavity, comprises at least one water-soluble polymer, a taste-masking effective amount of a sweetener, and a pharmaceutically active agent having a sufficiently unpleasant taste that it is desirably masked by the sweetener. For example, a buccal film was formulated containing dextromethorphan·HBr 22.7322, Amberlite IRP69 24.2477, xanthan gum 0.1165, locust bean gum 0.1365, carrageenan 0.5851, pullulan 31.2066, K sorbate 0.1170, menthol 3.908, peppermint flavor 0.3908, cherry flavor 0.3908, sour cherry 3.3871, Warm Sensation 0.8362, artificial masking flavor 0.6273, Succulence

0.3908, FD&C Red Number 40 0.0149, polysorbate 80 0.6826, Atmos 300 0.6826, glycerin 2.9256, mannitol 3.9008, and sucralose 2.7279 %.

AN 2003:892252 HCAPLUS <<LOGINID::20081006>>

DN 139:354513

TI Fast dissolving orally consumable films containing a sweetener

IN Kulkarni, Neema; Kumar, Lori D.; Sorg, Albert

PA USA

SO U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 395,104.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20030211136	A1	20031113	US 2003-423398	20030425 <--
	US 20030054034	A1	20030320	US 1999-395104	19990914 <--
	US 6596298	B2	20030722		
	CA 2520986	A1	20000406	CA 1999-2520986	19990923 <--
	CA 2520986	C	20071113		
	CA 2572461	A1	20000406	CA 1999-2572461	19990923 <--
	EP 1676557	A2	20060705	EP 2006-7765	19990923 <--
	EP 1676557	A3	20060906		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	US 20010022964	A1	20010920	US 2001-836474	20010418 <--
	US 7025983	B2	20060411		
	US 20030008008	A1	20030109	US 2002-81018	20020221 <--
	US 20030206941	A1	20031106	US 2003-418368	20030417 <--
	US 6923981	B2	20050802		
	US 20040136922	A1	20040715	US 2003-684778	20031014 <--
	US 7407669	B2	20080805		
	AU 2004233737	A1	20041111	AU 2004-233737	20040413 <--
	CA 2521735	A1	20041111	CA 2004-2521735	20040413 <--
	WO 2004096192	A1	20041111	WO 2004-IB1270	20040413 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1635796	A1	20060322	EP 2004-727069	20040413 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004009715	A	20060502	BR 2004-9715	20040413 <--
	CN 1809343	A	20060726	CN 2004-80017592	20040413 <--
	JP 2006524675	T	20061102	JP 2006-506532	20040413 <--
	US 20050031675	A1	20050210	US 2004-941193	20040915 <--
	US 20060039953	A1	20060223	US 2005-249874	20051013 <--
	IN 2005DN04675	A	20070817	IN 2005-DN4675	20051014 <--
	MX 2005PA11508	A	20051215	MX 2005-PA11508	20051025 <--
	US 20080020024	A1	20080124	US 2007-897152	20070829 <--
PRAI	US 1998-101798P	P	19980925	<--	
	US 1999-395104	A2	19990914	<--	
	CA 1999-2339353	A3	19990923	<--	
	CA 1999-2520986	A3	19990923	<--	
	EP 1999-969668	A3	19990923	<--	

US 2001-836474	A1	20010418	<--
US 2002-81018	B1	20020221	<--
US 2003-418368	A1	20030417	<--
US 2003-423398	A	20030425	<--
US 2003-423735	A1	20030425	<--
WO 2004-IB1270	W	20040413	

L9 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Preparation of aqueous clear solution dosage forms with bile acids

AB Compns. for pharmaceutical and other uses comprise clear aqueous solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aqueous solution. The compns. comprise (i) water, (ii) a bile acid component in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and (iii) either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a

range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition may further contain

a pharmaceutical compound, such as insulin, heparin, bismuth compds., amantadine and rimantadine. For example, solution dosage forms that did not show any precipitation at any pH were prepared containing ursodeoxycholic acid

(UDCA) 22

g, 1N NaOH 75 mL, chenodeoxycholic acid (CDCA) 3 g, maltodextrin 875 g, bismuth citrate 4 g, citric acid or lactic acid as needed, and purified water to make 1 L.

AN 2002:185616 HCAPLUS <<LOGINID::20081006>>

DN 136:252482

TI Preparation of aqueous clear solution dosage forms with bile acids

IN Yoo, Seo Hong

PA USA

SO U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U. S. 6,251,428.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 20020031558	A1	20020314	US 2001-778154	20010205 <--
	US 7303768	B2	20071204		
	US 6251428	B1	20010626	US 1999-357549	19990720 <--
	US 20030186933	A1	20031002	US 2002-309603	20021204 <--
	US 7166299	B2	20070123		
	US 20050158408	A1	20050721	US 2004-996945	20041124 <--
	AU 2004325203	A1	20060601	AU 2004-325203	20041124
	CA 2588168	A1	20060601	CA 2004-2588168	20041124
	EP 1819318	A1	20070822	EP 2004-812094	20041124
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 101065110	A	20071031	CN 2004-80044467	20041124
	BR 2004019213	A	20071218	BR 2004-19213	20041124
	JP 2008521800	T	20080626	JP 2007-543006	20041124
	AU 2006203315	A1	20060824	AU 2006-203315	20060803 <--
	AU 2006203315	B2	20080828		
	US 20070072828	A1	20070329	US 2006-522162	20060915 <--
	IN 2007CN02532	A	20070907	IN 2007-CN2532	20070612
	KR 2007098821	A	20071005	KR 2007-714361	20070622
	US 20080057133	A1	20080306	US 2007-934505	20071102 <--
PRAI	US 1998-94069P	P	19980724	<--	
	US 1999-357549	A2	19990720	<--	

US	2000-180268P	P	20000204	<--
AU	2001-236685	A3	20010205	<--
US	2001-778154	A3	20010205	<--
US	2004-996945	A2	20041124	
WO	2004-US39507	A	20041124	

RE.CNT 211 THERE ARE 211 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Fast dissolving orally consumable films containing an ion exchange resin as a taste masking agent

AB Physiol. acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer, such as pullulan, and a taste masked pharmaceutically active agent, such as dextromethorphan. The taste masking agent is preferably a sulfonated polymer ion exchange resin comprising polystyrene cross-linked with divinylbenzene, such as Amberlite. Methods for producing the films are also disclosed. For example, an antitussive film was prepared in accordance with the following procedure: (A) uncoated dextromethorphan hydrobromide was dissolved with mixing in the water, while maintaining the temperature at 75°, Amberlite resin was then mixed into the water with heating at 70-80°, and heating was stopped, water lost to evaporation was replaced, and the potassium sorbate and sweeteners were then added to the composition with mixing to form Preparation A. (B) The film-forming ingredients (i.e., xanthan gum, locust bean gum, carrageenan and pullulan) were mixed in a sep. container to form Preparation B. (C) Preparation B was slowly added to Preparation A with rapid mixing, followed by overnight mixing at a reduced rate to provide Preparation C. (D) The menthol was dissolved with mixing in the alc. in a sep. container. The Physcool was then dissolved with mixing therein. Monoammonium glycyrrhizinate, Polysorbate 80, Atmos 300 and flavors were then added to the mixture and mixed to enhanced uniformity to form Preparation D. (E)

Preparation

D, glycerin and mannitol were added to Preparation C with thorough mixing to provide Preparation E. Preparation E was poured on a mold and cast to form a film

of a desired thickness at room temperature The film was dried under warm air and cut to a desired dimension (dictated by, e.g., dosage and mouthfeel) for taste testing. The active film had a pleasing appearance and taste.

AN 2001:713109 HCAPLUS <<LOGINID::20081006>>

DN 135:262242

TI Fast dissolving orally consumable films containing an ion exchange resin as a taste masking agent

IN Bess, William S.; Kulkarni, Neema; Ambike, Suhas H.; Ramsay, Michael Paul

PA Warner-Lambert Company, USA

SO PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2001070194	A1	20010927	WO 2001-US2192	20010123 <--
	W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 7067116	B1	20060627	US 2000-535005	20000323 <--

CA 2402988	A1	20010927	CA 2001-2402988	20010123 <--
EP 1267829	A1	20030102	EP 2001-959912	20010123 <--
EP 1267829	B1	20060503		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003000035	A2	20030528	HU 2003-35	20010123 <--
BR 2001009378	A	20030603	BR 2001-9378	20010123 <--
JP 2003527410	T	20030916	JP 2001-568392	20010123 <--
JP 4145048	B2	20080903		
NZ 520961	A	20031031	NZ 2001-520961	20010123 <--
RU 2256442	C2	20050720	RU 2002-128354	20010123 <--
CN 1651092	A	20050810	CN 2004-10100395	20010123 <--
AU 2001229720	B2	20060202	AU 2001-229720	20010123 <--
AT 324864	T	20060615	AT 2001-959912	20010123 <--
EP 1674078	A2	20060628	EP 2006-7766	20010123 <--
EP 1674078	A3	20070725		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PT 1267829	T	20060731	PT 2001-959912	20010123 <--
ES 2261455	T3	20061116	ES 2001-959912	20010123 <--
TW 290474	B	20071201	TW 2001-90102651	20010207 <--
IN 2002MN01152	A	20040605	IN 2002-MN1152	20020823 <--
MX 2002PA08425	A	20021213	MX 2002-PA8425	20020828 <--
ZA 2002006963	A	20030721	ZA 2002-6963	20020829 <--
NO 2002004513	A	20020920	NO 2002-4513	20020920 <--
IN 2005MN01446	A	20070615	IN 2005-MN1446	20051229 <--
AU 2006201888	A1	20060525	AU 2006-201888	20060504 <--
US 20060204559	A1	20060914	US 2006-429547	20060505 <--
PRAI 2000-535005	A	20000323	<--	
EP 2001-959912	A3	20010123	<--	
WO 2001-US2192	W	20010123	<--	
IN 2002-MN1152	A3	20020823	<--	
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD				
ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L9 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Fast dissolving orally consumable films

AB Physiol. acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer such as pullulan. Edible films are disclosed that include pullulan and antimicrobially effective amts. of the essential oils thymol, Me salicylate, eucalyptol and menthol. The edible films are effective at killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath. The film can also contain pharmaceutically active agents. Methods for producing the films are also disclosed.

AN 2000:227470 HCAPLUS <<LOGINID::20081006>>

DN 132:255811

TI Fast dissolving orally consumable films

IN Leung, Sau-Hung Spence; Leone, Robert S.; Kumar, Lori Dee; Kulkarni, Neema; Sorg, Albert F.

PA Warner-Lambert Company, USA

SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2000018365	A2	20000406	WO 1999-US22115	19990923 <--
	WO 2000018365	A3	20001116		
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE,				

HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK,
 MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, UZ, VN,
 YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA	2339353	A1	20000406	CA 1999-2339353	19990923	<--
CA	2339353	C	20060124			
CA	2520986	A1	20000406	CA 1999-2520986	19990923	<--
CA	2520986	C	20071113			
CA	2572461	A1	20000406	CA 1999-2572461	19990923	<--
AU	9960593	A	20000417	AU 1999-60593	19990923	<--
AU	771862	B2	20040401			
EP	1115372	A2	20010718	EP 1999-969668	19990923	<--
EP	1115372	B1	20060517			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY						
JP	2002525306	T	20020813	JP 2000-571886	19990923	<--
EE	200100186	A	20020815	EE 2001-186	19990923	<--
TW	238067	B	20050821	TW 1999-88116383	19990923	<--
AT	326203	T	20060615	AT 1999-969668	19990923	<--
EP	1676557	A2	20060705	EP 2006-7765	19990923	<--
EP	1676557	A3	20060906			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL						
PT	1115372	T	20060731	PT 1999-969668	19990923	<--
ES	2260961	T3	20061101	ES 1999-969668	19990923	<--
TW	286943	B	20070921	TW 2005-94112737	19990923	<--
MX	2001PA01539	A	20020327	MX 2001-PA1539	20010209	<--
IN	2001MN00146	A	20051202	IN 2001-MN146	20010209	<--
ZA	2001001706	A	20030528	ZA 2001-1706	20010228	<--
NO	2001001476	A	20010322	NO 2001-1476	20010322	<--
US	20040136922	A1	20040715	US 2003-684778	20031014	<--
US	7407669	B2	20080805			
US	20050031675	A1	20050210	US 2004-941193	20040915	<--
IN	2005MN00637	A	20060519	IN 2005-MN637	20050620	<--
US	20060039953	A1	20060223	US 2005-249874	20051013	<--
IN	2007MN01374	A	20071102	IN 2007-MN1374	20070910	<--
PRAI	US 1998-101798P	P	19980925	<--		
	US 1999-395104	A3	19990914	<--		
	CA 1999-2339353	A3	19990923	<--		
	CA 1999-2520986	A3	19990923	<--		
	EP 1999-969668	A3	19990923	<--		
	WO 1999-US22115	W	19990923	<--		
	IN 2001-MN146	A3	20010209	<--		
	US 2001-836474	A1	20010418	<--		
	US 2002-81018	B1	20020221	<--		
	US 2003-418368	A1	20030417	<--		
	IN 2005-MN637	A3	20050620			

L9 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Drug interaction prevention in combination dose units

AB A combination therapy dose unit designed to prevent interaction between a plurality of active agents is prepared by charging particles of an active agent, charging particles of an inert particulate medium with a charge of opposite polarity, and allowing the charged particulate medium particles to adhere electrostatically to the charged particles of the active agent, thereby coating the active agent with inert particulate medium. Thereafter, other active agents can be treated in a similar manner and the electrostatically coated active agents can be combined, optionally together with other noncoated active agents, into a single combination

therapy dose unit such as a tablet. Thus, microparticles containing Bi subsalicylate, PVP (binder), lactose (filler), and an exploder were passed over a pos. electrode at 20,000-30,000 V and 50-120 mA to render the microparticle surface pos. charged. Micronized Mg stearate (inert particulate medium) was neg. charged by passing it over a neg. electrode in a similar manner, and was then used to form a microscopic coat around the pos. charged particles. Microparticles of tetracycline-HCl and of metronidazole were similarly pos. charged and coated with inert particulate medium, and all 3 coated active agents then blended, combined with binders, fillers, and disintegrants, and compressed into tablets containing Bi, tetracycline-HCl, and metronidazole in proportions of 100:200:200.

AN 1996:273495 HCAPLUS <<LOGINID::20081006>>

DN 124:298965

OREF 124:55219a,55222a

TI Drug interaction prevention in combination dose units

IN Moore, Trevor; Borody, Thomas Julius

PA Australia

SO PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9602236	A1	19960201	WO 1995-AU434	19950718 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9529184	A	19960216	AU 1995-29184	19950718 <--
PRAI	AU 1994-6952	A	19940720	<--	
	WO 1995-AU434	W	19950718	<--	